A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human ...

GARDASIL sales declined 18% to $1.6B due to lower demand in China, though demand outside China saw strong growth. WINREVAIR generated $200M in Q4 sales, with approximately 1,500 new patients ...

Sales of Gardasil, which is Merck’s second-largest product, declined 3% in 2024 due to a weak performance in China, which resulted from sluggish demand trends amid an economic slowdown.

Merck's HPV vaccine Gardasil 9. Courtesy photo Plaintiffs’ attorneys have asked a federal appeals court to reinstate more than 100 lawsuits tying the HPV vaccine Gardasil to autoimmune diseases.

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

Gardasil and Gardasil 9 are together Merck's second best-selling product, with global sales of $8.58 billion in 2024. U.S. patent protection expires in 2028.

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

FILE - A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. (AP Photo/Matt Rourke, File) Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street ...

Business Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China Feb. 4, 2025 at 6:18 am Updated Feb. 4, 2025 at 8:32 am ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.